Holders — by stockHoldings — by fund
GREAT POINT PARTNERS LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001281446
$418.5M
disclosed book value
43
positions
6.8%
largest position share
Positions, as of 2026-09-30
top 45 of 43 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | IBRXIMMUNITYBIO INCPUT | 3.0M | $28.3M | 6.8% |
| 2 | VERAVERA THERAPEUTICS INC | 808,717 | $26.1M | 6.2% |
| 3 | VORVOR BIOPHARMA INC | 1.1M | $21.5M | 5.1% |
| 4 | AMLXAMYLYX PHARMACEUTICALS INC | 700,000 | $20.4M | 4.9% |
| 5 | SGMTSAGIMET BIOSCIENCES INC | 2.0M | $19.4M | 4.6% |
| 6 | DFTXDEFINIUM THERAPEUTICS INC | 508,735 | $19.4M | 4.6% |
| 7 | IONSIONIS PHARMACEUTICALS INC | 420,000 | $18.8M | 4.5% |
| 8 | GMABGENMAB A/S | 525,000 | $18.7M | 4.5% |
| 9 | SLGLSOL-GEL TECHNOLOGIES LTD | 239,159 | $17.8M | 4.2% |
| 10 | ZURAZURA BIO LTD | 4.1M | $17.0M | 4.1% |
| 11 | LBRXLB PHARMACEUTICALS INC | 410,420 | $15.8M | 3.8% |
| 12 | ABVXABIVAX SA | 155,000 | $15.3M | 3.7% |
| 13 | ANNXANNEXON INC | 3.5M | $14.8M | 3.5% |
| 14 | BLTEBELITE BIO INC | 75,000 | $12.7M | 3% |
| 15 | EPRXEUPRAXIA PHARMACEUTICALS INC | 1.2M | $10.9M | 2.6% |
| 16 | NKTRNEKTAR THERAPEUTICS | 175,000 | $10.6M | 2.5% |
| 17 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 855,813 | $10.0M | 2.4% |
| 18 | CLYMCLIMB BIO INC | 800,000 | $9.2M | 2.2% |
| 19 | ABCLABCELLERA BIOLOGICS INC | 600,000 | $8.8M | 2.1% |
| 20 | NGNENEUROGENE INC | 300,000 | $8.3M | 2% |
| 21 | CMPSCOMPASS PATHWAYS PLC | 500,000 | $6.2M | 1.5% |
| 22 | JATTJATT II ACQUISITION CORP | 500,000 | $5.6M | 1.3% |
| 23 | IFRXINFLARX NV | 3.0M | $5.5M | 1.3% |
| 24 | RACCRESEARCH ALLIANCE CORP III | 504,891 | $5.5M | 1.3% |
| 25 | DRUGBRIGHT MINDS BIOSCIENCES INC | 109,603 | $5.5M | 1.3% |
| 26 | AMANAMANAT ACQUISITION CORP | 500,000 | $5.3M | 1.3% |
| 27 | ALTALTIMMUNE INC | 1.7M | $5.0M | 1.2% |
| 28 | JTTTJATT III ACQUISITION CORP | 450,000 | $5.0M | 1.2% |
| 29 | PHVSPHARVARIS N VPUT | 150,000 | $4.8M | 1.1% |
| 30 | SCYXSCYNEXIS INC | 944,292 | $4.7M | 1.1% |
| 31 | CGEMCULLINAN THERAPEUTICS INC | 300,000 | $4.6M | 1.1% |
| 32 | CTNMCONTINEUM THERAPEUTICS INCCALL | 300,000 | $4.0M | 1% |
| 33 | HELPCYBIN INC | 320,952 | $3.9M | 0.9% |
| 34 | RZLTREZOLUTE INC | 951,809 | $3.9M | 0.9% |
| 35 | IRDOPUS GENETICS INC | 776,881 | $3.8M | 0.9% |
| 36 | ELVNENLIVEN THERAPEUTICS INC | 70,000 | $3.2M | 0.8% |
| 37 | RLMDRELMADA THERAPEUTICS INC | 842,106 | $3.2M | 0.8% |
| 38 | DBVTDBV TECHNOLOGIES S A | 250,000 | $2.9M | 0.7% |
| 39 | EVMNEVOMMUNE INC | 325,000 | $2.7M | 0.6% |
| 40 | CTNMCONTINEUM THERAPEUTICS INC | 186,183 | $2.5M | 0.6% |
| 41 | ORKAORUKA THERAPEUTICS INC | 24,649 | $2.1M | 0.5% |
| 42 | HUMAHUMACYTE INC | 3.8M | $1.9M | 0.5% |
| 43 | RNTXREIN THERAPEUTICS INC | 1.7M | $1.3M | 0.3% |
| 44 | RACDRESEARCH ALLIANCE CORP IV | 106,396 | $1.3M | 0.3% |
| 45 | ANNXANNEXON INCCALL | 97,300 | $411,579 | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.